Michael Andreeff, M.D., Ph.D.

Professor of Medicine and Haas Chair in Genetics
Departments of Leukemia and Stem Cell Transplantation and Cellular Therapy
Chief, Section of Molecular Hematology and Therapy
University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd, Unit 0448, FC5.2026
Houston, TX 77030
United States of America
(713) 792-7260 office
(713) 404-3374 pager

Dr. Andreeff  received his M.D. and Ph.D. degrees at the University of Heidelberg, Germany, and additional training and faculty appointments  at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY, in the Departments of Pathology and Leukemia.

Dr. Andreeff has been a pioneer in flow cytometry since 1971, when he established the first flow cytometry laboratory at the University of Heidelberg ,and  organized the first European conference on flow cytometry. In 1977 he joined Memorial Sloan-Kettering Cancer Center in New York, NY, became head of the Leukemia Cell Biology and Hematopathology flow cytometry laboratory, organized the first Clinical Cytometry Conference in 1986 and the first Molecular Cytogenetics Conference in 1990.

 He is professor of medicine and holds the Paul and Mary Haas Chair in Genetics at MDACC. He has received uninterrupted NCI funding for over 30 years, serves as PI of the P01 grant entitled “The Therapy of AML” , participates as PI in MDACC Leukemia , Lymphoma, Ovarian and  Breast Cancer SPORE grants , the CML P01  and additional R21 and R01 grants. He has published over 450 peer-reviewed papers, 5 books and 75 book chapters

Dr Andreeff’s group has worked extensively on drug resistance in hematopoietic malignancies and breast cancer and  developed or co-developed several new therapeutic agents including the novel triterpenoids CDDO and CDDO-Me and  Bcl-2- , XIAP- , surviving-, MEK-   and HDM2- inhibitors. Over the last decade, his group has made major contributions to the understanding of micro-environment-mediated drug resistance and developed strategies to exploit the underlying mechanisms  for  the treatment of  hematopoietic and  epithelial malignancies. His group reported the role of bone marrow-derived multipotent mesenchymal stromal cells  (MSC) In tumor stroma formation and developed therapeutic strategies based on this discovery.